CIK 924223
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2018-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 61.48% | 18 |
| Unclassified | 30.69% | 16 |
| Life Sciences Tools & Services | 7.83% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | IONS | IONIS PHARMACEUTICALS INC | Health Care | 15.76% |
| 2 | INCY | INCYTE CORP | Health Care | 7.83% |
| 3 | NBIX | NEUROCRINE BIOSCIENCES INC | Health Care | 7.46% |
| 4 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Health Care | 6.01% |
| 5 | SAGE THERAPEUTICS INC COM | Unclassified | 5.50% | |
| 6 | CELGENE CORP | Unclassified | 5.22% | |
| 7 | AGIO | AGIOS PHARMACEUTICALS, INC. | Health Care | 5.05% |
| 8 | ALEXION PHARMACEUTICALS INC | Unclassified | 4.47% | |
| 9 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | Health Care | 3.83% |
| 10 | ESPR | Esperion Therapeutics, Inc. | Health Care | 3.56% |
19/35 names classified · sector 69.3% of weight · industry 69.3% · mkt cap 66.5%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 69.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 32% of book weight classified — the grid is NOT representative of the whole book.
Classified: 32.2% of book weight (8/21 names) · unclassified 67.8%: , IONS, AGIO, ESPR, ARGX, MRNA, NKTR, MGNX, WVE, VYGR +3 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | IONSIONIS PHARMACEUTICALS INC | 7,725,000 | $627M | 15.8% | TRIM −12% |
| 2 | INCYINCYTE CORP | 3,620,000 | $311M | 7.8% | TRIM −5% |
| 3 | NBIXNEUROCRINE BIOSCIENCES INC | 3,366,786 | $297M | 7.5% | HOLD |
| 4 | VRTXVERTEX PHARMACEUTICALS INC | 1,300,000 | $239M | 6.0% | TRIM −5% |
| 5 | SAGE THERAPEUTICS INC COM | 1,375,229 | $219M | 5.5% | HOLD |
| 6 | CELGENE CORP | 2,200,000 | $208M | 5.2% | TRIM −5% |
| 7 | AGIOAGIOS PHARMACEUTICALS INC | 2,978,134 | $201M | 5.0% | ADD 3% |
| 8 | ALEXION PHARMACEUTICALS INC | 1,314,428 | $178M | 4.5% | HOLD |
| 9 | ALNYALNYLAM PHARMACEUTICALS INC | 1,631,089 | $152M | 3.8% | ADD 4% |
| 10 | ESPRESPERION THERAPEUTICS INC NE | 3,522,964 | $141M | 3.6% | ADD 4% |
| 11 | RADIUS HEALTH INC | 6,781,685 | $135M | 3.4% | HOLD |
| 12 | HALOHALOZYME THERAPEUTICS INC | 8,322,860 | $134M | 3.4% | HOLD |
| 13 | ARGXARGENX SE | 904,739 | $113M | 2.8% | ADD 2% |
| 14 | MRNAMODERNA INC | 4,785,681 | $97M | 2.4% | HOLD |
| 15 | MYOVANT SCIENCES LTD | 3,597,882 | $86M | 2.2% | HOLD |
| 16 | INTERCEPT PHARMACEUTICALS IN | 696,976 | $78M | 2.0% | ADD 21% |
| 17 | GILDGILEAD SCIENCES INC | 1,142,204 | $74M | 1.9% | TRIM −14% |
| 18 | NKTRNEKTAR THERAPEUTICS COM NEW | 2,020,676 | $68M | 1.7% | ADD 46% |
| 19 | EXELEXELIXIS INC | 2,835,000 | $67M | 1.7% | HOLD |
| 20 | AKCEA THERAPEUTICS INC | 2,377,638 | $67M | 1.7% | HOLD |
| 21 | MYOKARDIA INC | 1,264,913 | $66M | 1.7% | ADD 44% |
| 22 | MGNXMACROGENICS INC | 3,400,000 | $61M | 1.5% | ADD 4% |
| 23 | WVEWAVE LIFE SCIENCES LTD | 1,465,002 | $57M | 1.4% | HOLD |
| 24 | VYGRVOYAGER THERAPEUTICS INC | 2,865,841 | $55M | 1.4% | HOLD |
| 25 | AUDENTES THERAPEUTICS INC. | 1,369,604 | $53M | 1.3% | ADD 78% |
| 26 | ALDER BIOPHARMACEUTICALS INC | 2,766,008 | $38M | 0.9% | HOLD |
| 27 | CRSPCRISPR THERAPEUTICS AG | 810,462 | $29M | 0.7% | NEW |
| 28 | SRRKSCHOLAR ROCK HLDG CORP | 1,476,839 | $28M | 0.7% | ADD 15% |
| 29 | INTRA-CELLULAR THERAPIES INC | 2,200,000 | $27M | 0.7% | HOLD |
| 30 | SGMOQSANGAMO THERAPEUTICS INC | 2,650,000 | $25M | 0.6% | ADD 96% |
| 31 | KEZAR LIFE SCIENCES INC | 1,220,503 | $22M | 0.5% | ADD 49% |
| 32 | G1 THERAPEUTICS INC | 671,925 | $11M | 0.3% | HOLD |
| 33 | CIDARA THERAPEUTICS INC COM NEW | 2,295,272 | $6M | 0.2% | HOLD |
| 34 | NVAXNOVAVAX INC | 8,330,000 | $5M | 0.1% | HOLD |
| 35 | TRANSPORTATION & LOGISTI | 91,336 | $3M | 0.1% | NEW |
Where this firm's principals came from and which firms its alumni went on to found.
